Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
OBJECTIVE To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms . METHOD In this placebo-controlled trial conducted from September 1 , 2001 , to August 31 , 2007 , 198 out patients > or = 40 years old with DSM-IV-diagnosed schizophrenia or schizoaffective disorder and subthreshold depressive symptoms were r and omly assigned to flexible-dose citalopram ( n = 104 ) or placebo ( n = 94 ) augmentation of their antipsychotic for 12 weeks . Depression was measured with the Hamilton Depression Rating Scale ( HDRS ) and Calgary Depression Rating Scale ( CDRS ) . Primary suicidal ideation measures were the Clinical Global Impressions-Severity of Suicide scale ( CGI-SS ) and the InterSePT Scale for Suicidal Thinking ( ISST ) ; secondary outcomes were the Scale for Suicidal Ideation ( SSI ) , Beck Hopelessness Scale ( BHS ) , HDRS item 3 , and CDRS item 8 . RESULTS Compared to placebo , at the final visit , citalopram was associated with lower BHS scores ( 4.21 vs 4.98 ; P < .05 ) and lower likelihood of having suicidal ideation on the ISST ( 17.7 % vs 38.7 % ; P < .005 ) and HDRS item 3 ( 14.4 % vs 22.6 % ; P < .05 ) . Among the 114 participants with no baseline suicidal ideation , there were no significant differences between citalopram and placebo regarding " emergent " ideation on either primary outcome . Among the 55 participants with baseline suicidal ideation , fewer treated with citalopram had endpoint ideation on the ISST ( 28.6 % vs 66.7 % ; P < .05 ) . Significantly more depression responders than nonresponders went from having baseline suicidal ideation to no suicidal ideation on both the ISST ( 75.0 % vs 31.4 % ; P < .05 ) and CGI-SS ( 84.6 % vs 31.3 % ; P < .05 ) . CONCLUSIONS Treatment-emergent suicidal ideation was no more common with citalopram than placebo . In participants with baseline suicidal ideation , citalopram reduced suicidal ideation , especially in those whose depressive symptoms responded to treatment
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .